All In Biotech

Drug Trial Radar · NCT01966653

Study Comparing Nitrofurantoin to Fosfomycin for Acute Urinary Tract Infection in Women

Randomised Clinical Trial Comparing Fosfomycin vs. Nitrofurantoin for Treatment of Uncomplicated Lower Urinary Tract Infection in Female Adults at Increased Risk of Antibiotic-resistant Bacterial Infection

Last checked: Nov 19, 2026Latest source record: May 2, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

600

Planned (sponsor's estimate)

Start

Oct 2013

Primary completion

May 2017

Study completion Aug 2017

Sponsor

Lead sponsor
University Hospital, GenevaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
European Commission
First posted
Oct 21, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Developed before the establishment of a structured process for drug assessment, nitrofurantoin is now being prescribed frequently given the rise in multi-resistant gram-negative pathogens. Doubts remain regarding fosfomycin's long-term clinical effectiveness. A randomized, controlled trial is needed to explore the clinical effectiveness and better define the side effect profiles of both nitrofurantoin and fosfomycin. This multi-center open trial will randomize 600 non-pregnant women at three international sites (200 each in Poland, Switzerland, and Israel) at increased risk for carriage of resistant uropathogens and with suspicion of uncomplicated lower urinary tract infection to receive either oral nitrofurantoin 100 mg three times daily for 5 days or a single 3g dose of oral fosfomycin. Patients will be followed for clinical and bacteriologic response at days 14 and 28 post therapy completion. The study hypothesis holds that nitrofurantoin will be superior to fosfomycin in clinical efficacy at final follow-up.

Conditions

  • Urinary Tract Infections
  • Cystitis

Interventions

  • nitrofurantoinDrug

    nitrofurantoin 100 mg po tid for 5 days

  • fosfomycinDrug

    fosfomycin 3g po single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with clinical cure, clinical failure, or indeterminate clinical response (see description below)Time frame: at 28 days post therapy completion

Locations

3 sites in 3 countries. Site status is shown where the registry gives one.

  • Tel Aviv University

    Tel Aviv, Israel

  • Lodz University Hospital

    Lodz, Poland

  • University Hospitals of Geneva

    Geneva, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.